Healthcare Technology Report March 27, 2024
California-based biotech Alumis has successfully secured $259 million in a series C financing round, marking the largest private biotech fundraising in 2024. The funding, co-led by Foresite Capital, Samsara BioCapital, and venBio Partners, will support Alumis’ pipeline of oral therapies targeting immune dysfunction. The substantial investment will also facilitate the launch of a phase 3 psoriasis trial for the lead asset, ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor. Alumis plans to initiate pivotal phase 3 trials for ESK-001 in the second half of the year, focusing on moderate to severe plaque psoriasis.
Alumis’s...
Today's Sponsors
Today's Sponsor